In 2025, China approved 76 innovative drugs, ranking first in the world.

At a symposium on the support of the Chinese medical device industry in "going global" held by the National Medical Insurance Administration, Deputy Director of the Drug Supervision Department of the National Medical Products Administration Zhou Le stated that in recent years, the National Medical Products Administration has systematically planned and reformed the supervision of the entire life cycle of drugs, including deepening the reform of the review and approval system, effectively stimulating the vitality of industrial innovation: By 2025, China had approved 76 innovative drugs, ranking first in the world in terms of quantity. In the same year, the annual transaction volume of Chinese innovative drugs going abroad exceeded 130 billion US dollars.